Amendments to the Claims

1. (Previously presented) A nucleic acid molecule comprising a $P66^{shc}$ coding sequence incorporating at least one mutation as compared to the wild type sequence or the sequence as shown in SEQ ID NO: 1 such that the protein encoded by the coding sequence has at least one serine residue absent or replaced by a different amino acid residue.

2. (Previously presented) A nucleic acid molecule according to claim 1 wherein the serine residue is selected from the group consisting of S17, S19, S20, S26, S28, S36, S38, S40, S41, S54, S60, S66, S80 and S102.

3. (Previously Presented) A nucleic acid molecule according to claim 1 wherein the serine residue is selected from the group consisting of S28, S36 and S54.

4. (Previously presented) A nucleic acid molecule according to claim 1 wherein the serine residue is S36 and is replaced by alanine ($p66^{shc}$S36A).

5. (Previously Presented) A polypeptide encoded by a nucleic acid molecule according to claim 1.

6. (Previously presented) A replicable vector comprising nucleic acid according to claim 1 operably linked to control sequences to direct its expression.

7. (Original) A host cell transformed with a vector according to claim 6.

8. (Original) A method of producing a modified $p66^{shc}$ polypeptide comprising culturing a host cell according to claim 7 so that the $p66^{shc}$ polypeptide is produced.

9. (Previously presented) A method of modulating resistance in cells to oxidative stress by affecting the $p66^{shc}$ signal transduction pathway in a cell, said method comprising the step of contacting said cell with an agent capable of modulating $p66^{shc}$ gene expression.

10. (Previously Presented) A method according to claim 9 wherein said agent is a nucleic acid molecule capable of hybridizing to nucleic acid encoding $p66^{shc}$ thereby reducing or preventing said p66shc thereby reducing or preventing said $p66^{shc}$ expression.

11. (Original) A method according to claim 9 wherein said agent is a vector comprising nucleic acid encoding $p66^{shc}$, said vector being capable of incorporating said nucleic acid into the genome of the cell so that the nucleic acid encoding p66shc is expressed in the cell.

12. (Previously presented) A method of increasing resistance in cells to oxidative stress comprising the step of disrupting the $p66^{shc}$ signaling pathway.

13. (Previously presented) A method according to claim 12 wherein said step of disrupting the $p66^{shc}$ affects the susceptibility of $p66^{shc}$ to phosphorylation.

14. (Previously Presented) A method according to claim 12 wherein said step of disrupting the $p66^{shc}$ pathway causes a mutant $p66^{shc}$ polypeptide to be expressed such that at least one serine residue present in the wild type $p66^{shc}$ is absent or replaced by a different amino acid residue.

15. (Previously Presented) A method according to claim 14 wherein said serine residue is S36 and is replaced by alanine.

16. (Original) A method according to claim 14 wherein said mutant polypeptide cannot be serine phosphorylated.

17. (Previously presented) A method according to claim 12 wherein said disruption affects the ability of a serine/threonine kinase, p38 or MAPK to phosphorylate $p66^{shc}$.

18. (Previously presented) A method according to claim 12 wherein the step of disrupting the p66shc signaling pathway includes contacting the cell with an antibody binding domain capable of specifically binding to the $p66^{shc}$ polypeptide such that its function is disrupted or prevented.

19. (Previously presented) A method according to claim 12 wherein said step of disrupting the $p66^{shc}$ signaling pathway includes disrupting the $p66^{shc}$ gene expression.

20. (Original) A method according to claim 19 wherein disruption of the $p66^{shc}$ gene expression includes contacting the cell with a substance capable of interfering with the expression of nucleic acid encoding the $p66^{shc}$ polypeptide so as to reduce or prevent its production.

21. (Previously presented) A method according to claim 20 wherein the substance is an antisense oligonucleotide capable of hybridizing to the nucleic acid encoding the p66shc polypeptide.

22. (Previously presented) A method for increasing cellular resistance to oxidative stress comprising administration of an effective amount of an agent which disrupts $p66^{shc}$ or a step in the $p66^{shc}$ signaling pathway in a pharmaceutically acceptable carrier.

23. (Previously presented) A method as claimed in claim 22 wherein said agent is an antisense oligonucleotide capable of specifically hybridizing to $p66^{shc}$ nucleic acid.

24. (Previously presented) A method according to claim 23 wherein said antisense oligonucleotide is RNA.

25. (Previously Presented) A method according to claim 23 wherein the $p66^{shc}$ nucleic acid sequence is shown in Fig. 5.

26. (Previously Presented) A method according to claim 22, wherein said agent is an antibody binding domain capable of specifically binding to a $p66^{shc}$ polypeptide or fragment thereof.

27. (Currently amended) A method as claimed in claim 22 wherein said agent is administered for the treatment of diseases selected from the group consisting of lung emphysema, myocardial infarction, stroke, premature aging, cell senescence, Parkinson's, Alzheimer, cancers and vascular complications of diabetes.

28. (Previously presented) A method of increasing resistance to tumor formation in a tissue comprising the step of increasing the expression of $p66^{shc}$ in said tissue.

29. (Original) A method according to claim 28 wherein the step of increasing the expression of $p66^{shc}$ includes contacting the tissue with an agent capable of increasing expression of $p66^{shc}$ gene.

30. (Original) A method according to claim 29 wherein said agent is a transcription factor.

31. (Original) A method according to claim 29 wherein said agent is a vector comprising nucleic acid encoding $p66^{shc}$ polypeptide said vector being capable incorporating said nucleic acid into the genome the cells of the tissue.

32. (Previously presented) A method of screening for compounds capable of modulating resistance in cells to oxidative stress by modulating the $p66^{shc}$ signaling pathway comprising contacting a candidate compound with a $p66^{shc}$ expression system; determining the amount of a compound of the signaling

pathway; and comparing said amount of the component with the amount of the component in the absence of said candidate compound.

33. (Original) A method according to claim 32 further comprising the step of preparing a pharmaceutical composition comprising the candidate compound capable of modulating a $p66^{shc}$ pathway and a pharmaceutical acceptable carrier.

34. (Previously presented) A method according to claim 32 wherein said step of determining the amount of a compound of the signaling pathway is an enzyme activity assay.

35. (Previously Presented) A method according claim 32 wherein said candidate compounds include nucleic acid sequences, antibody binding domains, and protein nucleic acids.

36. (Original) A method of reducing intracellular levels of reactive oxygen species (ROS) in a cell, said method comprising the step of contacting said cell with an agent capable of inhibiting the expression or activity of $p66^{shc}$ polypeptide.

37. (Previously presented) A method according to claim 36 wherein said agent is a nucleic acid molecule capable of specifically hybridizing with nucleic acid with the cell which codes for the p665hC polypeptide such that expression the $p66^{shc}$ polypeptide is reduced or prevented.

38. (Original) A method according to claim 36 wherein the agent is an antibody binding domain capable of specifically binding to the $p66^{shc}$ polypeptide such that its functions are inhibited or prevented.

39. (Canceled)

40. (Canceled)

41. (Canceled)

42. (Previously presented) A method of determining the presence or absence of a $p66^{shc}$ nucleic acid or a mutant, variant derivative or allele thereof in a biological sample, comprising the step of contacting said sample with a nucleic acid molecule capable of hybridizing specifically with said $p66^{shc}$ nucleic acid or a mutant, variant derivative or allele thereof and determining whether or not hybridization has taken place.

43. (Previously presented) A method of determining the presence or absence of a $p66^{shc}$ polypeptide or a mutant, variant derivative or allele thereof in a biological sample, comprising the step of contacting said sample with an antibody binding domain capable of binding $p66^{shc}$ or a mutant, variant derivative thereof and determining whether or not binding has taken place.

44. (Original) An expression system comprising a nucleic acid vector having a $p66^{shc}$ coding sequence or fragment thereof inserted therein.

45. (Previously presented) A method according to claim 10 wherein said agent is a vector comprising nucleic acid encoding $p66^{shc}$, which when expressed in a cell results in production of $p66^{shc}$.

46. (Previously presented) A method according to claim 10, wherein the nucleic acid molecule is an antisense oligonucleotide capable of hybridizing to the nucleic acid encoding the $p66^{shc}$ polypeptide.

47. (Previously presented) The method of claim 46, wherein said antisense oligonucleotide is RNA.

48. (Previously presented) A method according to claim 9, wherein said agent acts to increase resistance to oxidative stress in cells by disruption of the $p66^{shc}$ signaling pathway.

49. (Previously presented) A method according to claim 9, wherein said agent acts to increase cellular resistance to oxidative stress by disruption of $p66^{shc}$ or by disruption of a step in the $p66^{shc}$ signaling pathway.

50. (Previously presented) A method according to claim 49, wherein said agent is an antisense oligonucleotide which specifically hybridizes with a nucleic acid encoding $P66^{shc}$.

51. (Previously presented) A method according to claim 50, wherein said antisense oligonucleotide is RNA.

52. (Currently amended) A method according to claim 48, wherein said agent is administered for the treatment of a disease selected from the group consisting of arteriosclerosis, ischemic heart disease, lung emphysema, myocardial infraction, stroke, premature aging, cell senescence, Parkinson's, Alzheimer's, cancer and vascular complications of diabetes.